Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash & Current Investments (2019 - 2025)

Immunocore Holdings' Cash & Current Investments history spans 4 years, with the latest figure at $864.1 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 5.33% year-over-year to $864.1 million; the TTM value through Dec 2025 reached $864.1 million, up 5.33%, while the annual FY2025 figure was $864.1 million, 5.33% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $864.1 million at Immunocore Holdings, down from $892.4 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $901.3 million in Q3 2024 and bottomed at $402.5 million in Q4 2022.
  • The 4-year median for Cash & Current Investments is $848.3 million (2024), against an average of $773.5 million.
  • The largest annual shift saw Cash & Current Investments soared 85.34% in 2024 before it dropped 0.99% in 2025.
  • A 4-year view of Cash & Current Investments shows it stood at $402.5 million in 2022, then rose by 9.98% to $442.6 million in 2023, then skyrocketed by 85.34% to $820.4 million in 2024, then increased by 5.33% to $864.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Cash & Current Investments are $864.1 million (Q4 2025), $892.4 million (Q3 2025), and $882.8 million (Q2 2025).